Therapy for lysosomal storage disorders

Citations Over TimeTop 10% of 2009 papers

Abstract

In the last years, much progress has been achieved in the field of lysosomal storage disorders. In the past, no specific treatment was available for the affected patients; management mainly consisted of supportive care and treatment of complications. As orphan drug regulations, however, encouraged development of drugs for these disorders by granting marketing exclusivity for 10 years and other commercial benefits, enzyme replacement therapy became available for lysosomal storage disorders, such as Gaucher disease, Fabry disease, mucopolysaccharidoses type I, II, and VI, and Pompe disease. This review will summarize the efficacy and clinical status of hematopoietic stem cell transplantation, enzyme replacement, and substrate deprivation therapy, and describe new therapeutic perspectives currently under preclinical investigations such as chaperone-mediated therapy, stop-codon read-through therapy, and gene therapy.

Related Papers

• → Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases(2009)6 cited
• → Mutation identification of Fabry disease in families with other lysosomal storage disorders(2012)2 cited
• → Lysosomal leukocyte β-d-glucuronidase during enzyme replacement therapy in Fabry disease(2005)2 cited
• → Lysosomal Storage Diseases and Therapies(2013)
• → P 326. Developments in Stem Cell Transplantation in Lysosomal Storage Diseases—An Update on the Example of Mucopolysaccharidoses(2018)